Article
Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
Genes, chromosomes & cancer - 1 Apr 2018
Liu Liping, Liu Han, Shao Di, Liu Zu, Wang Jingjing, Deng Qiuhua, Tang Hailing, Yang Haihong, Zhang Yalei, Qiu Yuan, Cui Fei, Tan Meihua, Zhang Pan, Li Zhilong, Liu Jilong, Liang Wenhua, Wang Yuying, Peng Zhiyu, Wang Jian, Yang Huanming, Mao Mao, Kristiansen Karsten, Ye Mingzhi, He Jianxing
Abstract excerpt
Molecular analysis of potentially actionable mutations has become routine practice in oncological pathology. However, testing a wide range of oncogenes and mutations can be technically challenging because of limitations associated with tumor biopsy. Circulating tumor DNA (ctDNA) is a potential tool for the noninvasive profiling of tumors. In this study, we developed a next-generation sequencing (NGS)-based test...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.